BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 28092996)

  • 41. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
    Sawyer JR
    Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma.
    Chang H; Ning Y; Qi X; Yeung J; Xu W
    Br J Haematol; 2007 Oct; 139(1):51-4. PubMed ID: 17854306
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?
    Leiba M; Duek A; Amariglio N; Avigdor A; Benyamini N; Hardan I; Zilbershats I; Ganzel C; Shevetz O; Novikov I; Cohen Y; Ishoev G; Rozic G; Nagler A; Trakhtenbrot L
    Genes Chromosomes Cancer; 2016 Sep; 55(9):710-8. PubMed ID: 27152944
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Detection of chromosomal aberrations in multiple myeloma with fluorescence in situ hybridization].
    Cao P; Chen F; Cheng Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 37(10):983-9. PubMed ID: 23117450
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.
    Boyd KD; Ross FM; Tapper WJ; Chiecchio L; Dagrada G; Konn ZJ; Gonzalez D; Walker BA; Hockley SL; Wardell CP; Gregory WM; Child JA; Jackson GH; Davies FE; Morgan GJ;
    Genes Chromosomes Cancer; 2011 Oct; 50(10):765-74. PubMed ID: 21961181
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
    Oh S; Koo DH; Kwon MJ; Kim K; Suh C; Min CK; Yoon SS; Shin HJ; Jo DY; Kwak JY; Kim JS; Sohn SK; Joo YD; Eom HS; Kim SH; Kim YS; Kim C; Mun YC; Kim H; Lee DS; Lee JH;
    Ann Hematol; 2014 Aug; 93(8):1353-61. PubMed ID: 24671365
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.
    Reece D; Song KW; Fu T; Roland B; Chang H; Horsman DE; Mansoor A; Chen C; Masih-Khan E; Trieu Y; Bruyere H; Stewart DA; Bahlis NJ
    Blood; 2009 Jul; 114(3):522-5. PubMed ID: 19332768
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of acquired del(17p) in multiple myeloma.
    Lakshman A; Painuly U; Rajkumar SV; Ketterling RP; Kapoor P; Greipp PT; Dispenzieri A; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
    Blood Adv; 2019 Jul; 3(13):1930-1938. PubMed ID: 31248884
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fluorescence in situ hybridization analysis of chromosome aberrations in 60 Chinese patients with multiple myeloma.
    Gao X; Li C; Zhang R; Yang R; Qu X; Qiu H; Xu J; Lu H; Li J; Chen L
    Med Oncol; 2012 Sep; 29(3):2200-6. PubMed ID: 21611837
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation.
    Paul E; Sutlu T; Deneberg S; Alici E; Björkstrand B; Jansson M; Lerner R; Wallblom A; Gahrton G; Nahi H
    Oncol Rep; 2009 Jul; 22(1):137-42. PubMed ID: 19513515
    [TBL] [Abstract][Full Text] [Related]  

  • 51. t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome.
    An G; Xu Y; Shi L; Zou D; Deng S; Sui W; Xie Z; Hao M; Chang H; Qiu L
    Leuk Res; 2013 Oct; 37(10):1251-7. PubMed ID: 23927993
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Chang H; Qi X; Jiang A; Xu W; Young T; Reece D
    Bone Marrow Transplant; 2010 Jan; 45(1):117-21. PubMed ID: 19448682
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Cytogenetic Abnormalities and Outcomes of 117 Patients with Multiple Myeloma Detected by FISH].
    Zhai B; Zou DD; Yan JJ; Wang N; Wang LL; Zhu HL; Huang WR; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):127-30. PubMed ID: 26913408
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma.
    Li F; Xu Y; Deng S; Li Z; Zou D; Yi S; Sui W; Hao M; Qiu L
    Oncotarget; 2015 Nov; 6(35):38270-82. PubMed ID: 26516702
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China.
    Lai YY; Huang XJ; Cai Z; Cao XS; Chen FP; Chen XQ; Chen BA; Fang MY; Feng JF; Fu WL; Guo HY; Hou M; Hou J; Hu Y; Hu XT; Hu XM; Huang LQ; Jin J; Li JY; Li J; Li W; Liang YM; Liu T; Liu QF; Liu YH; Mao P; Ouyang J; Qiu LG; Qiu L; Shao CK; Shi B; Song YP; Sun ZM; Wang QS; Wang C; Wang JM; Wang YS; Wang Z; Wu JB; Wu YX; Xia RX; Xue YQ; Yang BZ; Yang G; Yang ZL; Yu L; Yuan Z; Zhang S; Zhang Y; Zhao HG; Zhao L; Zhou DB; Zou SH; Zhu YF
    Chin Med J (Engl); 2012 Aug; 125(15):2663-70. PubMed ID: 22931972
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.
    Sasaki K; Lu G; Saliba RM; Bashir Q; Hosing C; Popat U; Shah N; Parmar S; Dinh Y; Ahmed S; Shpall EJ; Kebriaei P; Shah JJ; Orlowski RZ; Champlin R; Qazilbash MH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1227-32. PubMed ID: 23733001
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.
    Kadam Amare PS; Jain H; Nikalje S; Sengar M; Menon H; Inamdar N; Subramanian PG; Gujral S; Shet T; Epari S; Nair R
    Indian J Med Res; 2016 Oct; 144(4):536-543. PubMed ID: 28256461
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combination of Genetic Aberration With International Staging System Classification for Stratification of Asian Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.
    Byun JM; Kim D; Shin DY; Kim I; Koh Y; Yoon SS
    In Vivo; 2019; 33(2):611-619. PubMed ID: 30804149
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.
    Qazilbash MH; Saliba RM; Ahmed B; Parikh G; Mendoza F; Ashraf N; Hosing C; Flosser T; Weber DM; Wang M; Couriel DR; Popat U; Kebriaei P; Alousi AM; Anderlini P; Naeem RC; Champlin RE; Giralt SA
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1066-72. PubMed ID: 17697969
    [TBL] [Abstract][Full Text] [Related]  

  • 60. At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China.
    Shen M; Yang G; Li X; Geng C; Huang Z; Chen W
    Leuk Lymphoma; 2021 Dec; 62(12):2992-3001. PubMed ID: 34219587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.